Prevention of Skin Cancer with nicotinamide in Transplant recipients
Phase 3
- Conditions
- Skin Neoplasms, transplant recipients, chemoprevention, Skin and Connective Tissue Diseases, Squamous Cell carcinoma, basal cell carcinoma, niacinamideC17800D018890C04588805
- Registration Number
- RBR-8ht6j7q
- Lead Sponsor
- Irmandade Santa Casa de Misericordia de Porto Alegre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients older than 18 years; transplanted at least one year ago; with diagnosis of at least two NMSC in the last 12 months; who accept to participate in the study and agree to take the medication or placebo, by signing an Informed Consent Form.
Exclusion Criteria
Patients who do not wish to participate in the study; patients with impaired renal; hepatic or clotting function; patients who had malignant internal organ tumors in the last 5 years or malignant tumor metastases; pregnant or lactating women; patients on hemodialysis or peritoneal dialysis; patients who underwent treatment for actinic keratoses in the last 4 weeks; patients using systemic retinoids or with previous use of nicotinamide in the last 4 weeks
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method